IP Library Granted Patent US 8,722,096
Granted Patent B2
US 8,722,096 · App. 12/302,260 · Granted May 13, 2014

Lipoic acid pellets

Inventors: Luigi Boltri (Agrate Brianza, IT); Flavio Fabiani (Milan, IT); Luigi Mapelli (Milan, IT); Annibale Salvi (Milan, IT); Paolo Magri' (Castel San Pietro, CH); Antonio Nardi (Paderno Dugnano, IT); Flavio Villani (Parma, IT)
Assignees: Aptalis Pharma Limited; Laboratorio Chimico Internazionale S.p.A.
A61K9/5078A61K9/1652C07D339/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,722,096
App. No.
12/302,260
Granted
May 13, 2014
Kind
B2
Abstract

Lipoic acid pellets are described, obtained from inert cores externally coated with lipoic acid. The so obtained active cores are coated with a first layer of insulating polymeric material and then with a polymeric coat that is insoluble at the gastric pH. Pellet are then formulated pharmaceutically, for instance in jelly capsules or controlled release capsules or as oral suspensions, dispersible powders, sachets, etc.

Claims (19)

1. Lipoic acid pellet, comprising an inert core coated with lipoic acid (active core) in an amount from 5 to 60 wt % of the active core, and further coated with a first insulating polymeric coat and with a second external gastroresistant polymeric coat, wherein the total weight of the insulating polymeric coat and the gastroresistant polymeric coat ranges from 5 to 60 wt % of the weight of the total pellet weight.

2. Pellet according to claim 1 , wherein the inert core comprises sucrose, microcrystalline cellulose cores or other inert materials.

3. Pellet according to claim 1 , wherein lipoic acid is R(+) lipoic acid, S(−) lipoic acid, a salt or a mixture thereof.

4. Pellet according to claim 1 , wherein the first insulating polymeric coat comprises hydroxypropylmethylcellulose or hydroxypropylcellulose.

5. Pellet according to claim 1 , wherein the second gastroresistant polymeric coat comprises one or more cellulose esters, polyvinyl acetate-phthalate, copolymers of methacrylic acid and methyl acrylate esters, and shellac.

6. Pellet according to claim 5 , wherein the second gastroresistant polymeric coat comprises one or more among cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, poly(methacrylic acid-co-methyl methacrylate) (1:1), poly(methacrylic acid-co-methyl methacrylate) (1:2), and poly(methacrylic acid-co-ethyl acrylate) (1:1).

7. Process for preparation of a lipoic acid pellet according to claim 1 , comprising the following steps:

(i) application of lipoic acid on inert cores to provide active cores;

(ii) application of a polymeric insulating coat on the active cores obtained in step (i);

(iii) application of a gastroresistant polymeric coat on the active cores obtained in step (ii);

(iv) drying and recovery of the coated active cores obtained in step (iii).

8. Pharmaceutical composition for oral administration, comprising the pellet of claim 1 , mixed with excipients suitable for pharmaceutical use.

9. Composition according to claim 8 , formulated in soft or hard jelly capsules, controlled release capsules, oral suspension, dispersible powder, or sachets.

10. Composition according to claim 8 , comprising amounts of lipoic acid ranging from 50 mg to 2 g per administration unit.

11. Nutritional supplement comprising a composition of claim 8 .

12. A nutritional supplement comprising the pellet according to claim 1 .

13. An additive for foodstuff comprising the pellet according to claim 1 .

14. The additive according to claim 13 , wherein the foodstuff has an acid pH.

15. A method for the treatment of pathological conditions responsive to lipoic acid treatment, comprising administering to a subject in need thereof an effective amount of lipoic acid pellet according to claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2016
From: APTALIS PHARMA LIMITED
To: ADARE PHARMACEUTICALS S.R.L.
Reel/Frame 038049/0136 →
CHANGE OF NAME Recorded Oct 7, 2011
From: EURAND PHARMACEUTICALS LIMITED
To: APTALIS PHARMA LIMITED
Reel/Frame 027033/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2009
From: BOLTRI, LUIGI; FABIANI, FLAVIO; MAPELLI, LUIGI; SALVI, ANNIBALE; MAGRI, PAOLO; NARDI, ANTONIO; VILLANI, FLAVIO
To: EURAND PHARMACEUTICALS LIMITED; LABORATORIO CHIMICO INTERNAZIONALE S.P.A.
Reel/Frame 022183/0750 →
Priority Claims (1)
IT MI2006A1024 · May 25, 2006 · national
Continuity (1)
Related Publication 20090117232A1 · May 7, 2009